Subscribe
patent-istock-579425600-duncan-andison
Duncan_Andison / iStockphoto.com
3 April 2017Americas

AbbVie fights to invalidate Novartis patents

AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus (HCV) are invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis upholds MS drug patent at Fed Circ
4 January 2022   Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.
Americas
Novartis accused of owing $47m in IP royalties
15 July 2021   Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.
Big Pharma
Novartis secures victory as MS drug patent is upheld
18 August 2020   In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
Novartis upholds MS drug patent at Fed Circ
4 January 2022   Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.
Americas
Novartis accused of owing $47m in IP royalties
15 July 2021   Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.
Big Pharma
Novartis secures victory as MS drug patent is upheld
18 August 2020   In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

More on this story

Americas
Novartis upholds MS drug patent at Fed Circ
4 January 2022   Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.
Americas
Novartis accused of owing $47m in IP royalties
15 July 2021   Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.
Big Pharma
Novartis secures victory as MS drug patent is upheld
18 August 2020   In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

More features

The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
The right formula: Minimising the cost of chemical and pharma patents
‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm